$CCTG premarket gap to $0.2390 from $0.28 prior close, down 15.9% on 25.8M shares. Running hot this session, these verticals can fade fast on the o… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cctg-pm-dn-watch&utm_term=scanner&s=CCTG
November 2, 2026 at 1:07 PM
$CCTG premarket gap to $0.2390 from $0.28 prior close, down 15.9% on 25.8M shares. Running hot this session, these verticals can fade fast on the o… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cctg-pm-dn-watch&utm_term=scanner&s=CCTG
$CCTG premarket gap to $0.3725 from $0.28 prior close, up 31.0% on 9,676,399 shares. Running hot this session, these verticals can fade fast on the… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cctg-pm-up-tape&utm_term=scanner&s=CCTG
November 2, 2026 at 12:35 PM
$CCTG premarket gap to $0.3725 from $0.28 prior close, up 31.0% on 9,676,399 shares. Running hot this session, these verticals can fade fast on the… https://tapeboard.com/go/bsky/scanner?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=cctg-pm-up-tape&utm_term=scanner&s=CCTG
🇬🇳 Guinée : payés à 550 000 GNF par mois, des contractuels temporaires réclament leur intégration à la fonction publique [Mediaguinee]
Guinée : payés à 550 000 GNF par mois, des contractuels temporaires réclament leur intégration à la fonction publique [Mediaguinee] - afropages.fr
Le Collectif des Contractuels Temporaires de Guinée (CCTG) réclame la régularisation de la situation administrative de ses membres, dont certains
twp.ai
November 1, 2026 at 8:55 AM
🇬🇳 Guinée : payés à 550 000 GNF par mois, des contractuels temporaires réclament leur intégration à la fonction publique [Mediaguinee]
🇬🇳 Guinée : « 10 ans au service de l’État pour 550 000 GNF », le cri de détresse des contractuels [Guinée7]
Guinée : « 10 ans au service de l’État pour 550 000 GNF », le cri de détresse des contractuels [Guinée7] - afropages.fr
Guinée- Réunis à la Bourse du Travail de Conakry ce samedi 31 octobre, les membres du Collectif des Contractuels Temporaires de Guinée (CCTG) ont lancé un appel au président Mamadi Doumbouya pour obte...
twp.ai
November 1, 2026 at 6:52 AM
🇬🇳 Guinée : « 10 ans au service de l’État pour 550 000 GNF », le cri de détresse des contractuels [Guinée7]
Can systemic treatment intensification reduce recurrence risk in high-risk localised prostate cancer? #ESMO26 presentation of interim results from the #DASLHiCaP #CCTG PR.22 international (ANZUP 1801) clinical trial. buff.ly/IokpCQt
October 24, 2026 at 5:09 PM
Can systemic treatment intensification reduce recurrence risk in high-risk localised prostate cancer? #ESMO26 presentation of interim results from the #DASLHiCaP #CCTG PR.22 international (ANZUP 1801) clinical trial. buff.ly/IokpCQt
Daniel Khalaf, MD, on patient-reported quality of life with docetaxel vs. lutetium-177-PSMA-617 in mCRPC from the CCTG PR21 trial. #ESMO26
Watch now: https://bit.ly/4zRF5n2
Watch now: https://bit.ly/4zRF5n2
October 25, 2026 at 6:46 PM
Daniel Khalaf, MD, on patient-reported quality of life with docetaxel vs. lutetium-177-PSMA-617 in mCRPC from the CCTG PR21 trial. #ESMO26
Watch now: https://bit.ly/4zRF5n2
Watch now: https://bit.ly/4zRF5n2
Andrew Redfern, MD, on CCTG MA.40/FINER: ipatasertib + fulvestrant kept its PFS benefit but did not improve OS in ER+/HER2− mBC after a CDK4/6 inhibitor. #ESMO26
Watch now: https://bit.ly/4skqDBu
Watch now: https://bit.ly/4skqDBu
October 24, 2026 at 10:54 PM
Andrew Redfern, MD, on CCTG MA.40/FINER: ipatasertib + fulvestrant kept its PFS benefit but did not improve OS in ER+/HER2− mBC after a CDK4/6 inhibitor. #ESMO26
Watch now: https://bit.ly/4skqDBu
Watch now: https://bit.ly/4skqDBu
#DDAmanda Flagged $CCTG : Already up 271%. DDAmanda Chart
Previous winners: $MPAA $SVRE $SDOT
Never miss another: https://DDAmanda.com
#DDAmanda
Previous winners: $MPAA $SVRE $SDOT
Never miss another: https://DDAmanda.com
#DDAmanda
October 5, 2026 at 2:03 PM
#DDAmanda Flagged $CCTG : Already up 271%. DDAmanda Chart
Previous winners: $MPAA $SVRE $SDOT
Never miss another: https://DDAmanda.com
#DDAmanda
Previous winners: $MPAA $SVRE $SDOT
Never miss another: https://DDAmanda.com
#DDAmanda
Today is National Day for Truth and Reconciliation and Every Child Matters Orange Shirt Day. #CCTG is honouring Residential School Survivors, their families, and communities, and recognizes the lasting impacts of Canada’s Residential School system. #EveryChildMatters #TruthAndReconciliation
September 30, 2026 at 12:03 PM
Today is National Day for Truth and Reconciliation and Every Child Matters Orange Shirt Day. #CCTG is honouring Residential School Survivors, their families, and communities, and recognizes the lasting impacts of Canada’s Residential School system. #EveryChildMatters #TruthAndReconciliation
Exciting #Kolbe follow-up session with these oncologists in the #CCTG VISION Program. By expanding their understanding of their instinctive problem-solving #talents, they are even better equipped to support improved patient cancer #treatments. Discover your natural #strengths https://loom.ly/vGIDZSE
September 29, 2026 at 4:04 PM
Exciting #Kolbe follow-up session with these oncologists in the #CCTG VISION Program. By expanding their understanding of their instinctive problem-solving #talents, they are even better equipped to support improved patient cancer #treatments. Discover your natural #strengths https://loom.ly/vGIDZSE
Exciting #Kolbe follow-up session with these oncologists in the #CCTG VISION Program. By expanding their understanding of their instinctive problem-solving #talents, they are even better equipped to support improved patient cancer #treatments. Discover your natural #strengths https://loom.ly/oRx7hoI
September 29, 2026 at 4:04 PM
Exciting #Kolbe follow-up session with these oncologists in the #CCTG VISION Program. By expanding their understanding of their instinctive problem-solving #talents, they are even better equipped to support improved patient cancer #treatments. Discover your natural #strengths https://loom.ly/oRx7hoI
Exciting #Kolbe follow-up session with these oncologists in the #CCTG VISION Program. By expanding their understanding of their instinctive problem-solving #talents, they are even better equipped to support improved patient cancer #treatments. Discover your natural #strengths https://loom.ly/IOhidEE
September 29, 2026 at 4:04 PM
Exciting #Kolbe follow-up session with these oncologists in the #CCTG VISION Program. By expanding their understanding of their instinctive problem-solving #talents, they are even better equipped to support improved patient cancer #treatments. Discover your natural #strengths https://loom.ly/IOhidEE
Shavonne - So Tell Me, Tell Me
www.youtube.com/watch?v=cCTg...
www.youtube.com/watch?v=cCTg...
Shavonne - So Tell Me, Tell Me
YouTube video by Aqueles Anos 80's
www.youtube.com
September 29, 2026 at 8:20 AM
Shavonne - So Tell Me, Tell Me
www.youtube.com/watch?v=cCTg...
www.youtube.com/watch?v=cCTg...
CCTG poster presentations at #IMS26 in Glasgow, Scotland 🏴 ! Dr. Annette Hay with the TACtful Trial poster and Dr. Florenica Comelles presents the MY13 trials in progress abstract poster (Study Chair Dr. Hira Mian)
September 28, 2026 at 12:00 PM
CCTG poster presentations at #IMS26 in Glasgow, Scotland 🏴 ! Dr. Annette Hay with the TACtful Trial poster and Dr. Florenica Comelles presents the MY13 trials in progress abstract poster (Study Chair Dr. Hira Mian)
👏Raffaella presenting at #EANO2026 today.
The ARGOS post hoc analysis of EORTC-1709-BTG/CCTG CE.8 (MIRAGE) explored the relationship between radiotherapy quality assurance (RTQA), uninvolved-brain dose, survival, and treatment-related toxicity in patients with glioblastoma.
The ARGOS post hoc analysis of EORTC-1709-BTG/CCTG CE.8 (MIRAGE) explored the relationship between radiotherapy quality assurance (RTQA), uninvolved-brain dose, survival, and treatment-related toxicity in patients with glioblastoma.
September 25, 2026 at 4:01 PM
👏Raffaella presenting at #EANO2026 today.
The ARGOS post hoc analysis of EORTC-1709-BTG/CCTG CE.8 (MIRAGE) explored the relationship between radiotherapy quality assurance (RTQA), uninvolved-brain dose, survival, and treatment-related toxicity in patients with glioblastoma.
The ARGOS post hoc analysis of EORTC-1709-BTG/CCTG CE.8 (MIRAGE) explored the relationship between radiotherapy quality assurance (RTQA), uninvolved-brain dose, survival, and treatment-related toxicity in patients with glioblastoma.
#CCTG is proud to be part of the The Marathon of Hope Cancer Centres Network working to unite Canadian researchers and improve the quality of life for cancer patients through precision oncology.
The Marathon Continues.
The Government of Canada has announced $80M for the next phase of the Marathon of Hope Cancer Centres Network, catalyzing up tp $160M with matching funds.
We’re getting closer to finishing what Terry started, but there’s more to do.
The next phase starts today.
The Government of Canada has announced $80M for the next phase of the Marathon of Hope Cancer Centres Network, catalyzing up tp $160M with matching funds.
We’re getting closer to finishing what Terry started, but there’s more to do.
The next phase starts today.
September 24, 2026 at 2:56 PM
#CCTG is proud to be part of the The Marathon of Hope Cancer Centres Network working to unite Canadian researchers and improve the quality of life for cancer patients through precision oncology.
The #CCTG PAC5 trial is now open to patient enrollment in Canada - to see if lanreotide can reduce the risk of postoperative pancreatic fistula (#POPF), one of the most important complications following #pancreatic cancer surgery. buff.ly/nDNpmIL
September 21, 2026 at 11:01 AM
The #CCTG PAC5 trial is now open to patient enrollment in Canada - to see if lanreotide can reduce the risk of postoperative pancreatic fistula (#POPF), one of the most important complications following #pancreatic cancer surgery. buff.ly/nDNpmIL
#CCTG is seeking applications for a Breast Cancer Patient Representative - volunteer role supporting the Breast Disease Site Committee, and the Patient Representative Committee. Encouraging applications from New Brunswick, Nova Scotia, PEI or Newfoundland and Labrador. How to apply> buff.ly/anDXXyE
September 17, 2026 at 11:01 AM
#CCTG is seeking applications for a Breast Cancer Patient Representative - volunteer role supporting the Breast Disease Site Committee, and the Patient Representative Committee. Encouraging applications from New Brunswick, Nova Scotia, PEI or Newfoundland and Labrador. How to apply> buff.ly/anDXXyE
Today is #WorldLymphomaDay and #CCTG is highlighting the IND245 clinical trial for people with mantle cell lymphoma receiving CAR-T therapy. The study is exploring whether two oral medications can improve outcomes and support patients through treatment. #WorldLymphomaDay #Lymphoma
buff.ly/uEgVeey
buff.ly/uEgVeey
September 15, 2026 at 11:30 AM
Today is #WorldLymphomaDay and #CCTG is highlighting the IND245 clinical trial for people with mantle cell lymphoma receiving CAR-T therapy. The study is exploring whether two oral medications can improve outcomes and support patients through treatment. #WorldLymphomaDay #Lymphoma
buff.ly/uEgVeey
buff.ly/uEgVeey
Tomorrow is #WorldLymphomaDay with a spotlight on the #CCTG IND244, clinical trial, for patients with primary central nervous system lymphoma evaluating a new treatment approach for patients who may not be able to receive intensive chemotherapy and stem cell transplantation.
buff.ly/js35Jnd
buff.ly/js35Jnd
September 14, 2026 at 11:30 AM
Tomorrow is #WorldLymphomaDay with a spotlight on the #CCTG IND244, clinical trial, for patients with primary central nervous system lymphoma evaluating a new treatment approach for patients who may not be able to receive intensive chemotherapy and stem cell transplantation.
buff.ly/js35Jnd
buff.ly/js35Jnd
September is #ProstateCancerAwarenessMonth and the #CCTG PR.24 trial is comparing higher-dose radiation delivered over a shorter period of time compared to the current way radiation therapy is used to treat #ProstateCancer - #ClinicalTrials #BlueSeptember
buff.ly/aBCMv1Z
buff.ly/aBCMv1Z
September 8, 2026 at 11:30 AM
September is #ProstateCancerAwarenessMonth and the #CCTG PR.24 trial is comparing higher-dose radiation delivered over a shorter period of time compared to the current way radiation therapy is used to treat #ProstateCancer - #ClinicalTrials #BlueSeptember
buff.ly/aBCMv1Z
buff.ly/aBCMv1Z
The #CCTG EN12 #RAINBO-ORANGE clinical trial has been funded through the #CIHR Project Grant - investigating surgery followed by radiotherapy and a type of oral endocrine therapy. www.ctg.queensu.ca/cctg_news/en...
September 4, 2026 at 11:01 AM
The #CCTG EN12 #RAINBO-ORANGE clinical trial has been funded through the #CIHR Project Grant - investigating surgery followed by radiotherapy and a type of oral endocrine therapy. www.ctg.queensu.ca/cctg_news/en...
A new #CCTG clinical trial, ALC.8, is open for people with newly diagnosed, untreated high-risk acute myeloid leukemia (#AML). As part of #myeloMATCH, the study is comparing four treatment combinations with standard therapy. #ClinicalTrials #CancerResearch
buff.ly/BVE1zY5
September 2, 2026 at 11:30 AM
A new #CCTG clinical trial, ALC.8, is open for people with newly diagnosed, untreated high-risk acute myeloid leukemia (#AML). As part of #myeloMATCH, the study is comparing four treatment combinations with standard therapy. #ClinicalTrials #CancerResearch
buff.ly/BVE1zY5
#CCTG is seeking two new members for its Quality of Life Committee! Applicants with an interest or expertise in patient-reported outcomes are encouraged to apply, with roles focused on brain cancer and supportive care. Apply by August 31! #CancerResearch #PatientReportedOutcomes
buff.ly/5UAqnCM
buff.ly/5UAqnCM
August 26, 2026 at 11:30 AM
#CCTG is seeking two new members for its Quality of Life Committee! Applicants with an interest or expertise in patient-reported outcomes are encouraged to apply, with roles focused on brain cancer and supportive care. Apply by August 31! #CancerResearch #PatientReportedOutcomes
buff.ly/5UAqnCM
buff.ly/5UAqnCM